Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Rating of “Hold” from Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have earned a consensus recommendation of “Hold” from the seven brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $4.25.

INO has been the subject of a number of recent research reports. HC Wainwright reduced their price objective on Inovio Pharmaceuticals from $3.00 to $2.50 and set a “neutral” rating for the company in a research note on Monday, June 1st. Weiss Ratings upgraded Inovio Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 16th. Oppenheimer reiterated an “outperform” rating on shares of Inovio Pharmaceuticals in a research note on Friday, March 13th. Finally, Wall Street Zen lowered Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, June 21st.

Hedge Funds Weigh In On Inovio Pharmaceuticals

A number of institutional investors have recently modified their holdings of INO. AQR Capital Management LLC purchased a new position in shares of Inovio Pharmaceuticals during the 1st quarter valued at about $120,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 5,894 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in shares of Inovio Pharmaceuticals during the 2nd quarter valued at about $234,000. Jane Street Group LLC raised its stake in shares of Inovio Pharmaceuticals by 221.2% during the 2nd quarter. Jane Street Group LLC now owns 39,683 shares of the biopharmaceutical company’s stock valued at $81,000 after buying an additional 27,329 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Inovio Pharmaceuticals by 1,667.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 65,206 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 61,516 shares in the last quarter. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Price Performance

Shares of INO stock opened at $1.10 on Wednesday. The firm has a market capitalization of $90.50 million, a price-to-earnings ratio of -0.76 and a beta of 1.49. The business has a fifty day moving average of $1.20 and a 200 day moving average of $1.50. Inovio Pharmaceuticals has a 1 year low of $1.03 and a 1 year high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02. As a group, equities research analysts expect that Inovio Pharmaceuticals will post -0.97 earnings per share for the current year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.